Protech Home Medical won’t be ruined by cyber theft, Beacon says

Protech Home Medical (Protech Home Medical Stock Quote, Chart TSXV:PTQ) has become victim of a cybercrime, one that has fleeced the company of $9.2 million, an amount which had been earmarked to repay its 7.5-per-cent non-convertible debentures. But fear not, says Doug Cooper, analyst for Beacon Securities, the issue won’t lead to a going concern for the healthcare company.

In-home patient monitoring and disease management company Protech announced the theft on Monday, saying that it was caused by a breach of its email system and that the company was working with authorities (RCMP, FBI and Hong Kong police) as well as a private cybersecurity firm in effort to recover the funds.

“Although this loss, if realized, is a setback for the company, given the work that we have done over the past several quarters, the company’s operations and margins are unaffected by these events and our balance sheet will remain in a healthy overall position,” said CEO and Chairman, Gregory Crawford, in a press release. “I am also very pleased to support the company with additional capital to enable us to redeem the Debentures and continue to make the substantial strides we have made since December 2017.”

Cooper says that while the theft is a setback for Protech, particularly concerning its near-term acquisition strategy, it’s not a company-breaker, for a number of reasons, saying that taking the theft into consideration, PTQ still has approximately $3 million in cash and $7 million of working capital.

“We remain steadfastly bullish of companies participating in the aging demographic segment given that as the Baby Boom population reaches the ‘Age of Illness,’ they will need more products/services of the kind that PTQ offers. This is, and will continue to provide, a tailwind for growth,” said Cooper in a client update on Tuesday.

“Furthermore, management has done an excellent job over the past several quarters expanding its EBITDA margin profile from 8 per cet in Q1/FY18 to 20 per cent in Q1/FY19,” he says.

The analyst says that the event has no impact on his EBITDA forecasts and that therefore he is not changing his estimates, which call for fiscal 2019 revenue and EBITDA of $88.7 million and $16.9 million, respectively, and fiscal 2020 revenue and EBITDA of $104.1 million and $20.8 million, respectively.

Cooper says that PTQ is now trading at 5x his fiscal 2019 estimates and 4x his fiscal 2020 forecasts, which puts it at a 50- to 65-per-cent discount to its peer group. He is maintaining his “Buy” rating with a reduced target of $2.50 (was $3.00), which he attributes to the company’s recent $15-million financing as well as the approximately $0.11 per share loss from the cybertheft. Cooper’s $2.50 target represents a projected return of 216 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: ptq
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

10 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

17 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

17 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

18 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago